2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Antoinette R. Tan, MD, MHSc, discusses the potential of the oral selective estrogen receptor degrader elacestrant being investigated in the phase 3 EMERALD trial in estrogen receptor–positive breast cancer.
Antoinette R. Tan, MD, MHSc, chief, Breast Medical Oncology, co-director, the Phase I Program, Levine Cancer Institute, chief, Medical Oncology, Atrium Health, Carolinas Medical Center-Pineville, clinical professor, the Department of Medicine, the University of North Carolina, discusses the potential of the oral selective estrogen receptor degrader (SERD) elacestrant (RAD-1901) being investigated inthe phase 3 EMERALD trial (NCT03778931) in estrogen receptor (ER)–positive breast cancer.
The phase 3 trial compared the efficacy and safety of elacestrant to standard-of-care fulvestrant (Faslodex) in patients whose disease has advanced on at least 1 prior endocrine therapy. Moreover, a new drug application has been submitted to the FDA, seeking the approval of elacestrant in ER–positive/HER2–negative breast cancer, supported by the results of this phase 3 trial.
The primary end point of the study looked at progression-free survival (PFS) in patients, which included patients whose disease had ESR1 mutations, Tan says. Moreover, results of the study showed that elacestrant improved PFS in patients at both 6 and 12 months when compared with fulvestrant, Tan explains. Overall, this is encouraging data, as this oral SERD is showing efficacy in a patient population who had previously been exposed to a CDK4/6 inhibitor, Tan concludes